Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparil + Temozolomide in Recurrent Glioblastoma
NCT04552977Phase 2Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of fluzoparib in glioblastoma (GBM), sponsored by Shandong Cancer Hospital. Status: unknown.
02
Drugs
fluzoparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04552977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552977.